Cytomegalovirus (CMV) is a common viral pathogen that influences the outcome of liver
transplantation. In addition to the direct effects of CMV syndrome and tissue-invasive …

The precise impact of valganciclovir as preventive therapy for cytomegalovirus (CMV) in
solid organ transplant (SOT) recipients is not fully defined. Data from studies using …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

Cytomegalovirus (CMV) is one of the most common viral pathogens causing clinical disease
in liver transplant recipients, and contributing to substantial morbidity and occasional …

Background Several anti-viral drugs have demonstrated efficacy in preventing
Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently …

Cytomegalovirus (CMV) is the most common viral pathogen that negatively impacts on the
outcome of liver transplantation. CMV cause febrile illness often accompanied by bone …

We systematically reviewed and meta-analyze the efficacy of universal prophylaxis (UP) and
preemptive (PE) strategies (using ganciclovir or valganciclovir) in preventing …

Cytomegalovirus (CMV) is a significant pathogen complicating the post‐transplant course of
organ recipients. In liver transplant patients, the febrile clinical illness caused by CMV may …

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …

The propensity of liver transplant recipients to develop more fulminant disease presentation
and a higher risk of disseminated disease due to a number of opportunistic infections …